Nestle signs $120 million deal with Seres for 'healthy gut' drugs

ZURICH (Reuters) - Nestle is investing in U.S.-based Seres Therapeutics for a third time in a year, this time injecting $120 million to develop and commercialize medicines aimed at restoring a healthy bacteriological balance in the human digestive system.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro